## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($23.05)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Mizuho | $29 | $24 | +21% |
| 2025-11-17 | JP Morgan | $31 | $33 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Mizuho | main | Neutral |
| 2025-11-17 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 4 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.8%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.5B |
| Beta | 0.67 |
| 52W Range | $13.40 - $27.73 |
| Short Interest | 8.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 30.6 |
| Current P/E | 30.5 |
| YoY Growth | -0.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.20% (CS: 74) | Neutral |
| RSI_14 | 63.4 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.060x | Above |
| vs SMA50 | 1.112x | Above |
| vs SMA200 | 1.187x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $24.85
- **Stop Loss:** $23.05 (7.2% risk)
- **Target:** $26.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 416
- **Position Value:** $10,337.60
- **Portfolio %:** 10.34%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*